




2026 Advances in Prostate Cancer Management

A Multidisciplinary Approach

OCTOBER 8-9, 2026

HYBRID SYMPOSIUM • IN-PERSON & VIRTUAL



Memorial Sloan Kettering
Cancer Center



Overview

This two-day course, presented by faculty from Memorial Sloan Kettering Cancer Center (MSK), will highlight the latest advances in the multidisciplinary management of prostate cancer.

Through comprehensive, state-of-the-art lectures and interactive discussions, participants will engage with expert faculty spanning radiology, pathology, surgery, radiation oncology, and medical oncology to exchange insights and explore collaborative approaches to prostate cancer care.

Sessions will cover the full continuum of care, including patient evaluation and risk assessment, active surveillance, focal therapy, local and systemic therapies, and the prevention and management of treatment-related side effects. Participants will also gain insights into emerging research and innovations shaping the future of prostate cancer care, including the latest scientific discoveries and clinical advances from MSK.

Target Audience

This program is intended for urologists, urologic oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professionals involved in the care of patients with prostate cancer. Participants may choose to **attend onsite at MSK or virtually**. Visit the **Registration** section for more information.



Syllabus

Following the course, participants will receive access to an online syllabus containing recordings of the faculty presentations and PDF copies of the presentation slides.

Continuing Education Credit

This activity has been approved to offer *AMA PRA Category 1 Credit(s)*[™], ABIM Maintenance of Certification, and ABS Continuous Certification. Nursing Continuing Professional Development credit is pending. Visit the **Accreditation** section for more information.



Scan here for full details and registration
or visit. msk.org/ProstateCourse

Thursday Agenda

October 8, 2026 | 8:00 a.m.–5:00 p.m. ET

TIME	SESSIONS
7:30 a.m.	Onsite Check-in and Breakfast Virtual participants should plan to join at 7:55 a.m. for the start of the program.
8:00 a.m.	Welcome and Opening Remarks

SESSION I

Contemporary Approaches to Prostate Cancer Diagnosis and Staging

8:15 a.m.	Prostate Cancer Screening in 2026: Advances in Risk Assessment and Early Detection
9:00 a.m.	Beyond an Elevated PSA: Integrating Genetics, Biomarkers, and Imaging
9:30 a.m.	TUMOR BOARD Active Surveillance or Treatment? Navigating Complex Clinical Decisions
10:30 a.m.	Break

SESSION II

Advanced Techniques and Emerging Technologies in Prostate Cancer Care

10:45 a.m.	Novel Robotic Technology in Urologic Oncology
11:15 a.m.	Advances in Prostate Biopsy: Techniques, Practical Pearls, and Billing Considerations
11:45 a.m.	PANEL DISCUSSION Emerging Techniques in Robotic Prostatectomy and Focal Therapy
12:30 p.m.	Lunch Break

SESSION III

Navigating High-Risk Prostate Cancer

1:15 p.m. **PANEL DISCUSSION**
Multidisciplinary Management of High-Risk Prostate Cancer: From Patient Selection to Treatment

2:15 p.m. **Prostate Cancer Pathology: Cribriform and Intraductal Features and Gleason Grade Quantification**

3:00 p.m. **Break**

3:15 p.m. **DEBATE**
Localized Prostate Cancer Recurrence After Radiation: Salvage Cryotherapy vs. Salvage Radiation Therapy

4:00 p.m. **DEBATE**
Pelvic Lymph Node Dissection in the PSMA Era: Is There Still a Role?

5:00 p.m. **Closing Remarks**

5:00–
6:00 p.m. **Networking Reception**
Enjoy hors d'oeuvres, refreshments, and an opportunity to connect with colleagues.

Friday Agenda

October 9, 2026 | 8:00 a.m.–3:30 p.m. ET

TIME	SESSIONS
7:30 a.m.	Onsite Check-in and Breakfast Virtual participants should plan to join at 7:55 a.m. for the start of the program.
8:00 a.m.	Welcome and Opening Remarks
8:05 a.m.	Keynote Address To be announced

SESSION IV

Evolving Strategies in Advanced Prostate Cancer

9:00 a.m.	DEBATE Lymph Node–Positive Prostate Cancer: Surgery vs. Radiation?
9:45 a.m.	Break
10:00 a.m.	PANEL DISCUSSION Biochemical Recurrence: Evaluation and Management
10:40 a.m.	DEBATE First-Line Treatment for Polymetastatic Prostate Cancer: Radioligand Therapy vs. Chemotherapy?
11:15 a.m.	DEBATE Metachronous Oligometastatic Prostate Cancer: SBRT Alone vs. SBRT with Systemic Therapy
11:45 a.m.	Lunch Break
12:30 p.m.	DEBATE PARP Inhibition in Androgen Pathway Modulator–Sensitive Disease: BRCA2-Selected Patients Only or All Patients?

1:00 p.m. **DEBATE**
**First-Line Treatment for Androgen Pathway
Modulator–Resistant Disease: Radioligand Therapy
vs. Chemotherapy?**

1:30 p.m. Break

1:45 p.m. **Neuroendocrine Prostate Cancer:
Evolving Treatment Strategies**

2:45 p.m. **PANEL DISCUSSION**
**The Clinical Dilemma: Navigating Treatment
Decisions in Neuroendocrine Prostate Cancer**

3:30 p.m. **Closing Remarks**



Scan here for full details and registration
or visit. [**msk.org/ProstateCourse**](https://msk.org/ProstateCourse)


MSK Faculty

Course Directors



Behfar Ehdaie, MD, MPH

Associate Attending
Urology Service
Department of Surgery



Michael J. Morris, MD

Steven A. Greenberg Chair in Prostate Cancer Research
Attending; Prostate Cancer Section Head
Genitourinary Oncology Service
Department of Medicine



Himanshu Nagar, MD, MS

Director, Genitourinary Program
Manhattan Chief of External Beam Radiotherapy
Department of Radiation Oncology

A complete faculty list will be announced shortly.

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships are mitigated prior to the commencement of the activity.



Objectives

At the conclusion of this course, learners will be able to:

- Evaluate contemporary evidence and guideline recommendations for the management of localized and advanced prostate cancer, including active surveillance, focal therapy, surgery, radiation therapy, and systemic treatment options.
- Apply clinical, pathologic, genomic, and imaging data to risk stratification and individualized treatment planning for patients across the prostate cancer disease continuum.
- Interpret the appropriate use and clinical implications of genomic testing, biomarkers, and PSMA PET imaging to support diagnostic, prognostic, and therapeutic decision-making.
- Compare and select evidence-based treatment strategies for patients with advanced prostate cancer, including the integration and sequencing of emerging systemic therapies.
- Integrate multidisciplinary perspectives from urology, medical oncology, radiation oncology, radiology, and pathology to optimize patient-centered prostate cancer care and improve clinical outcomes.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved to offer the following credit types.

- *AMA PRA Category 1 Credit(s)*[™]
- ABIM Maintenance of Certification (MOC)
- ABS Continuous Certification (CC)

The following credits are pending approval:

- Nursing Continuing Professional Development (NCPD) Credit



Registration

Early discounted rates are available through August 13, 2026.

Early Rates

- Physicians (MDs, PhDs, DOs): \$500
- Advanced Practice Providers: \$350
- Nurses and Other Healthcare Professionals: \$300
- Residents and Fellows: \$100
- Industry Professionals: Not applicable (general rates apply)*

General Rates (After August 13, 2026)

- Physicians (MDs, PhDs, DOs): \$600
- Advanced Practice Providers: \$450
- Nurses and Other Healthcare Professionals: \$400
- Residents and Fellows: \$200
- Industry Professionals: \$1,050*

MSK employees receive complimentary registration for all CME programs by signing in with MSK credentials (SSO).

Discounted registration is available for select groups, including students, MSK alumni/affiliates, and participants from low- and lower-middle-income countries. For additional details, visit the course website.

*An **industry professional** is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.



Scan here for full details and registration
or visit. msk.org/ProstateCourse



Memorial Sloan Kettering
Cancer Center

Continuing Medical Education

VISIT US ONLINE

msk.org/cme

[Instagram/MSKcontinuingmedicaleducation](https://www.instagram.com/MSKcontinuingmedicaleducation)

[LinkedIn /showcase/MSK-CME](https://www.linkedin.com/showcase/MSK-CME)

[Facebook/MSKCME](https://www.facebook.com/MSKCME)

[X/MSKCME](https://twitter.com/MSKCME)